In conclusion, this study demonstrates the feasibility of locoregional IL-13Rα2-targeted CAR-T cell therapy in high-grade glioma, offering significant translational insights crucial for advancing CAR-T cell therapies in glioma treatment. The gene discussed is IL13RA2; the disease is central nervous system cancer.